ROCKVILLE, MD — For decades, the field of pharmacogenomics—the study of how genes influence an individual’s response to medications—has operated under a relatively narrow lens. Traditionally, researchers have focused on identifying single gene-drug pairs, attempting to pinpoint how a specific genetic variant dictates whether a patient will metabolize a drug effectively or suffer a dangerous adverse reaction.
However, as of October 23, 2026, the American Society of Human Genetics (ASHG) has signaled a paradigm shift. Moving beyond the "one gene, one drug" model, a new generation of scientists is integrating multiomic data, functional genomics, and massive real-world health datasets to construct a more holistic, inclusive, and actionable picture of human drug response.
The Evolution of Precision Medicine
The traditional pharmacogenomic model, while revolutionary, often fails to account for the biological complexity of the human body. While single-gene variants are essential for understanding drug metabolism—such as the well-known interactions between the CYP2D6 gene and various antidepressants or opioids—they represent only a fraction of the story.
In a trainee-led session at the ASHG, emerging researchers are arguing that pharmacogenomics must evolve to incorporate the "interactome." By combining transcriptomics, proteomics, and epigenomics with clinical data from electronic health records (EHRs), scientists are beginning to identify the subtle, cumulative factors that determine why a treatment works for one person but fails for another.
"We are moving from a static snapshot to a dynamic movie," explains a representative from the ASHG. "By examining how cellular models respond to drug perturbations across multiple omics layers, we aren’t just seeing the genetic ‘blueprint’; we are seeing the biological ‘factory’ in action."
Chronology of a Scientific Shift
The transition toward multiomic pharmacogenomics did not happen overnight. It is the result of a decade-long convergence of several technological and analytical breakthroughs:
- 2016–2019: The Foundation of Scale. The rise of massive biobanks (such as the UK Biobank and the All of Us Research Program) provided the statistical power necessary to detect smaller, common genetic variants that were previously invisible in smaller study cohorts.
- 2020–2023: The Functional Genomics Boom. The integration of CRISPR-based screening allowed researchers to move beyond observational studies. By "perturbing" cellular models with drugs, scientists could observe real-time physiological responses, validating clinical hypotheses in the laboratory.
- 2024–2026: The Inclusion Revolution. A concerted effort to address the "diversity gap" in genomics has taken center stage. Researchers began prioritizing populations historically underrepresented in genetic studies, recognizing that the "standard" reference genome was failing to capture the global variation in drug response.
- 2026 and Beyond: The Integration Phase. The current focus is the marriage of "big data" from EHRs with deep molecular profiling, aiming to create clinical decision-support tools that are as nuanced as the patients they serve.
Supporting Data: Why Complexity Matters
The central thesis of this new wave of research is that drug response is rarely the result of a single "switch." While disease-associated variants often have small effects, pharmacogenomic variants can have profound impacts on treatment efficacy, dosing requirements, and the risk of severe adverse events.
The Power of Biobanks
Current research presented by the ASHG highlights that while biobanks offer unprecedented scale, they are not without their challenges. The "quality" of a biobank is defined by:
- Phenotype Definition: Inconsistent coding in EHRs can lead to "noisy" data. Researchers are now developing standardized algorithms to clean this data, ensuring that "adverse drug reaction" means the same thing across different healthcare systems.
- Population Representation: Analysis of historical data shows that findings derived from European-ancestry cohorts often fail to translate to other global populations. By specifically recruiting from diverse ancestral backgrounds, current studies are identifying "actionable" variants that were previously missed, preventing health inequities in future prescription practices.
Functional Assays and Drug Perturbation
One of the most promising areas of study involves functional genomics. By taking patient-derived cells and exposing them to specific drugs in a controlled environment, researchers can observe how the cell’s entire molecular machinery reacts. This "omics profiling" captures the influence of the environment, diet, and concurrent medications—factors that traditional genetic testing often ignores.
Official Perspectives from the ASHG
The American Society of Human Genetics, which represents nearly 8,000 of the world’s leading researchers and clinicians, views this shift as a critical step toward the maturation of the field. By placing trainees and early-career scientists at the center of this dialogue, the ASHG is fostering a culture that prioritizes long-term, systemic solutions over short-term "low-hanging fruit."
"The focus is no longer just on ‘what gene?’ but ‘what context?’" the Society notes. Their leadership emphasizes that the future of the field depends on:
- Data Interoperability: Creating systems where genomic data can "speak" to clinical EHRs seamlessly.
- Ethical Implementation: Ensuring that as we learn more about individual variations, we protect patient privacy and prevent the misuse of genetic data in insurance or employment.
- Advocacy: Pushing for policy changes that encourage the routine collection of pharmacogenomic data in clinical settings, thereby moving the science from the laboratory bench to the bedside.
Clinical Implications: A New Standard of Care
The implications of this shift are profound for both providers and patients. If researchers can successfully integrate multiomic and environmental data into clinical practice, the "trial and error" method of prescribing medication could become a relic of the past.
Personalized Dosing
Instead of starting a patient on a standard dose of a high-risk medication (such as anticoagulants or chemotherapy) and waiting for a potential adverse reaction, clinicians could eventually use a "digital twin" model. By inputting a patient’s multiomic profile into a predictive model, doctors could calculate the optimal dose before the first pill is even swallowed.
Closing the Health Equity Gap
One of the most significant moral and scientific imperatives of this new era is the inclusion of historically understudied populations. The current ASHG discourse emphasizes that if precision medicine is to be truly effective, it must be universally applicable. By identifying variants that are common in non-European populations, the field is finally addressing the bias that has historically skewed pharmacological research.
Managing Environmental and Social Influences
Pharmacogenomics is finally beginning to acknowledge the "exposome"—the measure of all the exposures of an individual in a lifetime and how those exposures relate to health. By accounting for social determinants of health and environmental factors alongside genetic data, the next generation of clinical tools will be able to explain why two people with identical genotypes might respond differently to the same medication.
Conclusion: The Path Forward
The journey from identifying single-gene markers to understanding the full, complex, multiomic landscape of drug response is long, but the trajectory is clear. As the ASHG continues to lead this dialogue, the scientific community is moving closer to a vision of healthcare where treatment is not merely reactive, but deeply informed by the unique biological and environmental narrative of every patient.
While challenges regarding data quality, algorithmic bias, and clinical implementation remain, the enthusiasm within the field is palpable. By embracing complexity rather than simplifying it, researchers are paving the way for a new standard of care—one that is more inclusive, more accurate, and ultimately, more human.
About the American Society of Human Genetics (ASHG)
The American Society of Human Genetics (ASHG) is the leading global organization advancing the science of human genetics and genomics. Representing nearly 8,000 researchers, clinicians, genetic counselors, educators, and other professionals, ASHG drives progress in understanding the human genome and its role in health and disease. Learn more at www.ashg.org.
About the Author
